Advertisements


We’re so unprepared for finding an Alzheimer’s treatment

Finding an Alzheimer’s drug could be a breakthrough — that leads to a massive wait list......»»

Category: topSource: washpostNov 15th, 2017

KU Med hosts trial of Novartis treatment to prevent Alzheimer"s

T.....»»

Category: topSource: bizjournalsNov 7th, 2017

It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now (BIIB, VTVT, MRK, LLY, ROG, AZN)

AP/Alastair GrantThe search for an Alzheimer's disease treatment has been unsuccessful for the past 14 years.  The latest failure came in September, when Axovan.....»»

Category: topSource: businessinsiderOct 8th, 2017

Expect More Downside In Axovant Sciences

Shares of Axovant Sciences Ltd (NASDAQ: AXON) plummeted more than 70 percent after the company's late-stage trial involving its therapy for the treatment of Alzheimer's failed to meet its primary Latest Ratings for AXON Dat.....»»

Category: blogSource: benzingaOct 5th, 2017

Gene Discovery Explains Why We Relapse and Could Lead to New Treatment

The finding could lead to a drug to block these underlying factors......»»

Category: topSource: newsweekSep 27th, 2017

Alzheimer"s Drug: Promising Treatment From Axovant Fails Clinical Trial

Intepirdine did not demonstrate improvements in cognition and functioning in patients with mild-to-moderate Alzheimer's disease......»»

Category: topSource: newsweekSep 26th, 2017

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease......»»

Category: blogSource: 247wallstSep 26th, 2017

UPDATE: Axovant shares tumble 71% after late-stage trial of Alzheimer"s treatment fails to meet primary goals

Axovant Sciences Ltd. shares cratered 71% in premarket trade Tuesday, after the company said a late-stage trial of a.....»»

Category: topSource: marketwatchSep 26th, 2017

Cancer Clinical Trials: How New Search Tools Make it Easier for Patients to Find the Treatment They Need

Sometimes, a cancer patient’s best chance is getting into a clinical trial. But finding the right one can be as hard as finding an IV in a haystack......»»

Category: topSource: newsweekJul 20th, 2017

UAB finding success in new cancer trials

The University of Alabama at Birmingham's part in nationwide clinical trials and research for breast cancer treatment is helping uncover new treatments and results. Doctors at UAB, in conjunction with other university and researchers, have discov.....»»

Category: topSource: bizjournalsJun 26th, 2017

Analyst: Neurotrope"s Bryostatin-1 Trial Data Justifies Additional Studies

Shares of Neurotrope Inc (NASDAQ: NTRP), a biopharmaceutical company focused on developing a therapy called bryostatin-1 for the treatment of Alzheimer's disease, lost more than half of its value on Monday.....»»

Category: blogSource: benzingaMay 1st, 2017

Neurotrope Alzheimer"s Phase 2 Trial Data Coming On Monday

Shares of Neurotrope Inc (NASDAQ: NTRP), a clinical-stage biopharmaceutical company that develops therapies for the treatment of Alzheimer's and neurodegenerative diseases, shot higher by more than 15 percent early Friday morning. read more.....»»

Category: blogSource: benzingaApr 28th, 2017

Novartis Tests New Alzheimer"s Drugs on People Who Don"t Have the Disease

Subjects at high risk of developing Alzheimer’s—but who don’t actually have the disease—are being recruited to help test two experimental treatments from Novartis AG, in a new focus on preventive treatment......»»

Category: smallbizSource: wsjApr 22nd, 2017

Neurotrope Nears Breakthrough In New Alzheimer"s Treatment

Neurotrope Nears Breakthrough In New Alzheimer"s Treatment.....»»

Category: topSource: seekingalphaApr 3rd, 2017

Alzheimer"s drug stumbles in clinical trial, Colorado company plans to keep developing it

A Colorado biotech company’s experimental Alzheimer’s treatment didn’t help patients in a clinical trial as was hoped, but the company says that may have been the result of changing the drug’s formulation. Boulder-based Accera Inc. plans f.....»»

Category: topSource: bizjournalsFeb 28th, 2017

After Merck Stops Study, What Remains Of The Alzheimer"s Drug Pipeline?

Merck & Co, Inc. (NYSE: MRK) Tuesday reported it was halting its Phase 3 study of Alzheimer's treatment verubecestat in people with mild to moderate Alzheimer's disease (AD) afte read more.....»»

Category: blogSource: benzingaFeb 16th, 2017

Merck halts trial of once "promising" Alzheimer"s drug

US pharmaceutical giant Merck announced it is halting a clinical trial on a drug once touted as a promising treatment for Alzheimer's disease, saying studies show it does not work......»»

Category: topSource: moneycentralFeb 15th, 2017

Another Potential Alzheimer"s Disease Treatment Bites the Dust: What"s Next?

Merck's verubecestat becomes the latest casualty in treating Alzheimer's disease. Is there any hope in sight for this dreaded disease?.....»»

Category: topSource: foxnewsFeb 15th, 2017

Pharma giant Merck is stopping a key Alzheimer"s trial because there"s "virtually no chance of finding a positive clinical effect" (MRK)

AP/Alastair GrantFeb 14 (Reuters) - Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an exte.....»»

Category: topSource: businessinsiderFeb 14th, 2017

An experimental Alzheimer"s drug just failed two key trials, dashing any last hopes for the treatment

Lawrence Berkeley National Laboratory(Reuters) - Two remaining late-stage clinical trials testing an experimental Alzh.....»»

Category: topSource: businessinsiderFeb 8th, 2017

AbbVie to Start Study on Alzheimer"s Treatment

The treatment is aimed at early-onset Alzheimer's diseaseRelated Stocks: ABBV,.....»»

Category: blogSource: gurufocusJan 29th, 2017